A detailed history of Brown, Lisle/Cummings, Inc. transactions in Precigen, Inc. stock. As of the latest transaction made, Brown, Lisle/Cummings, Inc. holds 1,500 shares of PGEN stock, worth $1,425. This represents 0.0% of its overall portfolio holdings.

Number of Shares
1,500
Previous 2,250 33.33%
Holding current value
$1,425
Previous $3.56 Million 60.03%
% of portfolio
0.0%
Previous 0.0%

Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 18, 2024

SELL
$0.91 - $1.88 $682 - $1,410
-750 Reduced 33.33%
1,500 $1.42 Million
Q2 2024

Jul 17, 2024

BUY
$1.27 - $1.75 $2,857 - $3,937
2,250 New
2,250 $3.56 Million

Others Institutions Holding PGEN

About PRECIGEN, INC.


  • Ticker PGEN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 208,150,000
  • Market Cap $198M
  • Description
  • Precigen, Inc. discovers and develops the next generation of gene and cellular therapies in the United States. It also provides disease-modifying therapeutics; genetically engineered swine for regenerative medicine applications; and reproductive and embryo transfer technologies. In addition, the company offers UltraVector platform that incorpora...
More about PGEN
Track This Portfolio

Track Brown, Lisle/Cummings, Inc. Portfolio

Follow Brown, Lisle/Cummings, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Brown, Lisle/Cummings, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Brown, Lisle/Cummings, Inc. with notifications on news.